Qualigen Therapeutics, Inc. announced that on May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of the company, provided her resignation to the Company, which will become effective June 16, 2023 (Effective Date). Ms. Broidrick's departure is not related to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Effective as of the Effective Date, Ms. Broidrick will resign from all officer and director positions with the Company and its subsidiaries.

In connection with her resignation, the Company intends to enter into a separation agreement and general release with Ms. Broidrick.